Local complement-targeted intervention in periodontitis: Proof-of-concept using a C5a receptor (CD88) antagonist

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5442-5448

  Abe, Toshiharu ^a   Hosur, Kavita B ^a   Hajishengallis, Evlambia ^a   Reis, Edimara S ^b   Ricklin, Daniel ^b   Lambris, John D ^b   Hajishengallis, George ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALVEOLAR BONE LOSS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; MOUSE; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL;

ANIMALS; BACTEROIDACEAE INFECTIONS; DOWN-REGULATION; DRUG SYNERGISM; GINGIVA; IMMUNITY, INNATE; INJECTIONS; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPEPTIDES; MICE; PEPTIDES, CYCLIC; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; RECEPTOR CROSS-TALK; RECEPTOR, ANAPHYLATOXIN C5A; TOLL-LIKE RECEPTOR 2;

EID: 84869761067     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202339     Document Type: Article

References (53)

1. Pihlstrom, B. L., B. S. Michalowicz, and N. W. Johnson. 2005. Periodontal diseases. Lancet 366: 1809-1820. (Pubitemid 41642647)
2. Darveau, R. P. 2010. Periodontitis: a polymicrobial disruption of host homeostasis. Nat. Rev. Microbiol. 8: 481-490.
3. Hajishengallis, G., and R. J. Lamont. Beyond the red complex and into more complexity: the Polymicrobial Synergy and Dysbiosis (PSD) model of periodontal disease etiology. Mol. Oral Microbiol. doi: 10.1111/j.2041-1014. 2012.00663.x.
4. Darveau, R. P., G. Hajishengallis, and M. A. Curtis. 2012. Porphyromonas gingivalis as a potential community activist for disease. J. Dent. Res. 91: 816-820.
5. Hajishengallis, G., R. P. Darveau, and M. A. Curtis. 2012. The keystone-pathogen hypothesis. Nat. Rev. Microbiol. 10: 717-725.
6. Hajishengallis, G., S. Liang, M. A. Payne, A. Hashim, R. Jotwani, M. A. Eskan, M. L. McIntosh, A. Alsam, K. L. Kirkwood, J. D. Lambris, et al. 2011. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 10: 497-506.
7. Gaffen, S. L., and G. Hajishengallis. 2008. A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J. Dent. Res. 87: 817-828.
8. Van Dyke, T. E. 2008. The management of inflammation in periodontal disease. J. Periodontol. 79(Suppl. 8): 1601-1608.
9. Demmer, R. T., and P. N. Papapanou. 2010. Epidemiologic patterns of chronic and aggressive periodontitis. Periodontol. 2000 53: 28-44.
10. Genco, R. J., and T. E. Van Dyke. 2010. Prevention: Reducing the risk of CVD in patients with periodontitis. Nat Rev Cardiol 7: 479-480.
11. Lalla, E., and P. N. Papapanou. 2011. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 7: 738-748.
12. Awano, S., T. Ansai, Y. Takata, I. Soh, S. Akifusa, T. Hamasaki, A. Yoshida, K. Sonoki, K. Fujisawa, and T. Takehara. 2008. Oral health and mortality risk from pneumonia in the elderly. J. Dent. Res. 87: 334-339.
13. Tonetti, M. S., F. D'Aiuto, L. Nibali, A. Donald, C. Storry, M. Parkar, J. Suvan, A. D. Hingorani, P. Vallance, and J. Deanfield. 2007. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 356: 911-920. (Pubitemid 46339910)
14. Jeffcoat, M., S. Parry, M. Sammel, B. Clothier, A. Catlin, and G. Macones. 2011. Periodontal infection and preterm birth: successful periodontal therapy reduces the risk of preterm birth. BJOG 118: 250-256.
15. Lundberg, K., N. Wegner, T. Yucel-Lindberg, and P. J. Venables. 2010. Periodontitis in RA - the citrullinated enolase connection. Nat Rev Rheumatol 6: 727-730.
16. Brown, L. J., B. A. Johns, and T. P. Wall. 2002. The economics of periodontal diseases. Periodontol. 2000 29: 223-234.
17. Beikler, T., and T. F. Flemmig. 2011. Oral biofilm-associated diseases: trends and implications for quality of life, systemic health and expenditures. Periodontol. 2000 55: 87-103.
18. Hajishengallis, G., and J. D. Lambris. 2010. Crosstalk pathways between Tolllike receptors and the complement system. Trends Immunol. 31: 154-163.
19. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
20. Patters, M. R., C. E. Niekrash, and N. P. Lang. 1989. Assessment of complement cleavage in gingival fluid during experimental gingivitis in man. J. Clin. Periodontol. 16: 33-37.
21. Nikolopoulou-Papaconstantinou, A. A., A. C. Johannessen, and T. Kristoffersen. 1987. Deposits of immunoglobulins, complement, and immune complexes in inflamed human gingiva. Acta Odontol. Scand. 45: 187-193.
22. Schenkein, H. A., and R. J. Genco. 1977. Gingival fluid and serum in periodontal diseases. II. Evidence for cleavage of complement components C3, C3 proactivator (factor B) and C4 in gingival fluid. J. Periodontol. 48: 778-784. (Pubitemid 8254483)
23. Hajishengallis, G. 2010. Complement and periodontitis. Biochem. Pharmacol. 80: 1992-2001.
24. Liang, S., J. L. Krauss, H. Domon, M. L. McIntosh, K. B. Hosur, H. Qu, F. Li, A. Tzekou, J. D. Lambris, and G. Hajishengallis. 2011. The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J. Immunol. 186: 869-877.
25. Zhang, X., Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J. D. Lambris, R. A. Wetsel, T. Miwa, and W. C. Song. 2007. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110: 228-236. (Pubitemid 47026839)
26. Baker, P. J., M. Dixon, and D. C. Roopenian. 2000. Genetic control of susceptibility to Porphyromonas gingivalis-induced alveolar bone loss in mice. Infect. Immun. 68: 5864-5868.
27. Finch, A. M., A. K. Wong, N. J. Paczkowski, S. K. Wadi, D. J. Craik, D. P. Fairlie, and S. M. Taylor. 1999. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42: 1965-1974. (Pubitemid 29269629)
28. Wang, M., J. L. Krauss, H. Domon, K. B. Hosur, S. Liang, P. Magotti, M. Triantafilou, K. Triantafilou, J. D. Lambris, and G. Hajishengallis. 2010. Microbial hijacking of complement-Toll-like receptor crosstalk. Sci. Signal. 3: ra11.
29. Lin, X., X. Han, T. Kawai, and M. A. Taubman. 2011. Antibody to receptor activator of NF-κB ligand ameliorates T cell-mediated periodontal bone resorption. Infect. Immun. 79: 911-917.
30. McIntosh, M. L., and G. Hajishengallis. 2012. Inhibition of Porphyromonas gingivalis-induced periodontal bone loss by CXCR4 antagonist treatment. Mol. Oral Microbiol. doi: 10.1111/j.2041-1014.2012.00657.x.
31. Graves, D. T., D. Fine, Y. T. Teng, T. E. Van Dyke, and G. Hajishengallis. 2008. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J. Clin. Periodontol. 35: 89-105.
32. Mahanonda, R., and S. Pichyangkul. 2007. Toll-like receptors and their role in periodontal health and disease. Periodontol. 2000 43: 41-55.
33. Krauss, J. L., J. Potempa, J.D. Lambris, and G. Hajishengallis. 2010. Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontol. 2000 52: 141-162.
34. Zhang, P., J. Liu, Q. Xu, G. Harber, X. Feng, S. M. Michalek, and J. Katz. 2011. TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-κB. J. Biol. Chem. 286: 24159-24169.
35. Rojo-Botello, N. R., A. L. García-Hernández, and L. Moreno-Fierros. 2012. Expression of toll-like receptors 2, 4 and 9 is increased in gingival tissue from patients with type 2 diabetes and chronic periodontitis. J. Periodontal Res. 47: 62-73.
36. Burns, E., G. Bachrach, L. Shapira, and G. Nussbaum. 2006. Cutting Edge: TLR2 is required for the innate response to Porphyromonas gingivalis: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. J. Immunol. 177: 8296-8300. (Pubitemid 44893789)
37. Hajishengallis, G. 2010. Too old to fight? Aging and its toll on innate immunity. Mol Oral Microbiol 25: 25-37.
38. Kornman, K. S. 2006. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am. J. Clin. Nutr. 83: 475S-483S. (Pubitemid 44713222)
39. Kolls, J. K., and A. Lindén. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476. (Pubitemid 39370503)
40. Hajishengallis, G. 2009. Toll gates to periodontal host modulation and vaccine therapy. Periodontol. 2000 51: 181-207.
41. Hasturk, H., A. Kantarci, and T. E. Van Dyke. 2012. Paradigm shift in the pharmacological management of periodontal diseases. Front Oral Biol 15: 160-176.
42. Armitage, G. C. 2002. Classifying periodontal diseases - a long-standing dilemma. Periodontol. 2000 30: 9-23.
43. Heitz-Mayfield, L. J. 2005. Disease progression: identification of high-risk groups and individuals for periodontitis. J. Clin. Periodontol. 32(Suppl 6): 196-209. (Pubitemid 41391065)
44. Deas, D. E., S. A. Mackey, and H. T. McDonnell. 2003. Systemic disease and periodontitis: manifestations of neutrophil dysfunction. Periodontol. 2000 32: 82-104. (Pubitemid 37487572)
45. Graves, D. 2008. Cytokines that promote periodontal tissue destruction. J. Periodontol. 79(Suppl. 8): 1585-1591.
46. Assuma, R., T. Oates, D. Cochran, S. Amar, and D. T. Graves. 1998. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J. Immunol. 160: 403-409. (Pubitemid 28116755)
47. Ohyama, H., N. Kato-Kogoe, A. Kuhara, F. Nishimura, K. Nakasho, K. Yamanegi, N. Yamada, M. Hata, J. Yamane, and N. Terada. 2009. The involvement of IL-23 and the Th17 pathway in periodontitis. J. Dent. Res. 88: 633-638.
48. Cardoso, C. R., G. P. Garlet, G. E. Crippa, A. L. Rosa, W. M. Júnior, M. A. Rossi, and J. S. Silva. 2009. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol. Immunol. 24: 1-6.
49. Vernal, R., N. Dutzan, A. Chaparro, J. Puente, M. Antonieta Valenzuela, and J. Gamonal. 2005. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J. Clin. Periodontol. 32: 383-389. (Pubitemid 40569601)
50. Eskan, M. A., R. Jotwani, T. Abe, J. Chmelar, J. H. Lim, S. Liang, P. A. Ciero, J. L. Krauss, F. Li, M. Rauner, et al. 2012. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat. Immunol. 13: 465-473.
51. Breivik, T., Y. Gundersen, P. Gjermo, S. M. Taylor, T. M. Woodruff, and P. K. Opstad. 2011. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J. Periodontal Res. 46: 643-647.
52. Qu, H., D. Ricklin, and J. D. Lambris. 2009. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47: 185-195.
53. Woodruff, T. M., K. S. Nandakumar, and F. Tedesco. 2011. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48: 1631-1642.